ClinicalTrials.gg
CompletedNCT05464459HAPYUpdated Nov 9, 2026

Pyrocarbon Interposition Arthroplasty of the Elbow

An interventional study of Novel elbow procedure in Osteoarthritis of Elbow, sponsored by Wrightington, Wigan and Leigh NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Wrightington, Wigan and Leigh NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Osteoarthritis with a site in United Kingdom — 14 open to participants now, 38 under way, 1 of them phase 3. Osteoarthritis · United Kingdom.

Enrollment
107th of 114
10 · median 108
Started
2022
with 6 others
No phase
59 of 167
5 open now
Registered
149th of 167
by date

Among the 167 studies in Osteoarthritis with a site in United Kingdom, this one is the 107th largest by enrollment of the 114 interventional ones that give a count, is one of 7 that started in 2022, is one of 59 with no phase, and was the 149th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

14 of the 167 studies in Osteoarthritis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Osteoarthritis with a site in United Kingdom, or all of them as a file.
02

Study summary

The current study will be a prospective observational study (or collective case study in a small, carefully selected cohort of consenting patients with advanced arthritis. This study would be classified as a stage I study according the IDEAL framework for surgical innovation

Read the detailed description

Osteoarthritis (OA) of the elbow is associated with pain and loss of motion, which can have a dramatic impact on overall upper limb function due to the inability to position the hand to carry out activities of daily living. OA is characterised by osteophyte formation of the olecranon, coronoid and olecranon fossae, whilst the ulnohumeral and radiohumeral joint spaces may be relatively well preserved. The osteophytes cause terminal extension and flexion pain and impingement, whilst the limited arc of movement is often relatively pain-free. Loose bodies are also commonly present and can cause mechanical locking. Pain throughout the limited range of movement however, indicates joint destruction. This can be confirmed radiographically, which in contrast to the typical OA presentation described above, shows articular cartilage loss with narrowing or obliteration of the entire joint space, not usually seen in primary osteoarthritis. The pathologies in which loss of joint space is more commonly seen are post-septic arthritis, post-traumatic arthritis and inflammatory arthritis.

Total elbow arthroplasty (TEA) is thought to be an effective treatment for a range of pathologies including rheumatoid arthritis, late stage primary osteoarthritis, acute fracture and post-traumatic arthritis. However, it has been reported in the literature that younger patients undergoing TEA may experience earlier failure of the implant and higher complication rates. This is thought to be linked to higher functional demands placed on the implant due to greater occupational loading or participation in more demanding leisure activities. For this reason, other viable alternative to TEA are being sought by surgeons for younger patients with high functional demands.

Interposition arthroplasty has been proposed as an alternative to TEA for younger patients in the literature with various surgical techniques described. According to Thomas, the basic principle of interposition arthroplasty of the elbow is to perform a resection of the opposing bone ends and place something in between the distal humerus and the olecranon, which will then theoretically allow movement to occur without painful grinding of the joint.

Two of the major risks of TEA are aseptic loosening and periprosthetic infection. In the event of a significant joint infection, revision of the TEA procedure is often necessary and may be performed as a two-stage operation. Initially the prosthesis is removed and the infection is treated, a process that often involves the use of an antibiotic-impregnated spacer and oral antibiotics. If appropriate, once the infection is eradicated, a new prosthesis will be implanted. Cases have however been documented in the literature where the patients in receipt of spherical antibiotic cement spacers are satisfied with the movement and pain relief provided by the spacer, and subsequently decline re-implantation of a second prosthesis and. This has led the current author to question whether interposition arthroplasty using a spherical joint spacer may be a viable alternative to TEA in young patients with higher functional demands in whom there is a greater risk of premature aseptic loosening after TEA.

Pyrocarbon interposition implants have been successfully used in the small joints of the hand, wrist and foot, and more recently their use has been trialed in the shoulder with acceptable outcomes . Pyrocarbon is deemed an ideal material for the manufacture of orthopaedic implants due to its strength, resistance to wear and resistance to fatigue. It is also stated in the literature that there have been no reports of periarticular infiltration or reaction to pyrocarbon particles transmitted by the blood or lymphatic systems into organs such as the brain, kidneys or liver.

In the current study, we propose to perform interposition arthroplasty of the elbow using a spherical pyrocarbon implant normally used in the hand and wrist ('HAPY' pyrocarbon sphere, Wright Medical, USA), in a small case series of specially selected young patients with advanced arthritis who would otherwise require a total elbow arthroplasty.

Eligible patients attending the current author's clinic with advanced arthritis of the elbow, who are unsuitable for TEA due to their young age and high functional demands, will be invited to be part of the study. They will undergo the same pre and post-operative radiographic investigations as those undergoing TEA; A/P and lateral X-Ray views of the elbow at approximately 3 weeks, 3 months, 6 months, 12 months and 24 months. They will also complete patient reported outcome measures (PROMs) both pre-operatively, and at each of their post-operative clinic visits, as per routine practice within the host NHS Trust. Each of the PROMs to be used in this study will be a validated measure of upper limb function suitable for use in those with elbow pathology. An 11 point numerical rating scale for measurement of pain level will also be completed at each time-point in addition to goniometric measurement of elbow range of movement using a standardised technique and recording of adverse events. It is usual practice within the host NHS Trust for patients undergoing TEA to be reviewed following surgery at approximately 3 weeks, 3 months, 6 months, one year and 2 years. The same approximate follow-up schedule will be followed for patients undergoing the study procedure unless early problems are identified and there is a clinical need for more frequent follow-up assessment.

The protocol has been sent for external independent scientific review. The outcome of which has been enclosed alongside this protocol for review by the committee.

It will be made clear to all participants that pyrocarbon interposition arthroplasty of the elbow is an innovative and novel procedure and that the alternatives to this treatment would be TEA or continued conservative management. If the procedure fails to provide an acceptable outcome, the patient would then be offered a revision to a TEA. The previous interposition arthroplasty should not compromise a subsequent total elbow replacement as the bone resection is limited.

The previous literature relating to the use of spherical cement spacers in the elbow and the use of pyrocarbon interposition arthroplasty in other joints, leads us to believe that the proposed procedure in this study would prove a viable alternative for young patients with advanced arthritis of the elbow joint. However, for patient safety, a data monitoring committee will scrutinise the early data and if the complication rate is unacceptable or outcome unsatisfactory, the study will be terminated. The findings of this study, regardless of the number of participants or the success of the procedure, will be submitted for publication to further advance this field of orthopaedic practice.

The study data will be subject to internal scrutiny at 6 monthly intervals by colleagues within the upper limb unit at Wrightington, and external scrutiny by an external expert in the field.

03

Conditions studied

  • Osteoarthritis of Elbow

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically fit for surgery
  • Advanced osteoarthritis, post-traumatic arthritis, or post-septic arthritis
  • Severe inflammatory arthritis without severe bone destruction - Larsen grade III or less
  • Failed conservative treatment
  • Unsuitable for TEA due to high functional demands

Exclusion criteria

Exclusion Criteria:

  • Severe inflammatory arthritis with severe bone destruction
  • Arthritis suitable for treatment with arthroscopic debridement.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    HAPY interposition elbow replacement

    HAPY is a pyrocarbon sphere for use as an interposition joint replacement. In this study, the implant is being used as a novel procedure in the Elbow (outside approved label usage)

    Procedure: Novel elbow procedure

Interventions

  • ProcedureNovel elbow procedure

    A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.

06

What researchers measure

Primary outcomes

  1. Safety and acceptability

    The principal research objective is to assess the safety and acceptability of interposition arthroplasty of the elbow using a spherical pyrocarbon implant in a prospective consecutive case series of carefully selected patients.

    Time frame: 24 months

Secondary outcomes

  1. Motion Analysis

    Secondary Objective using motion analysis (special equipment to measure small movements and changes in elbow biomechanics) will be to quantify elbow joint Range of Movement and stability pre-operatively, and at 3- and 6-months post-operatively following interposition elbow arthroplasty and to compare this to a sex-matched group of patients after total elbow replacement.

    Time frame: 24 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2026, 47 months.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's 47 months is above that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Sep 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 19, 2022
StartActual
Oct 17, 2022
Primary completionActual
Oct 7, 2026was Sep 2026
CompletionActual
Oct 7, 2026was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 9, 2026
Primary completion
Sep 30, 2026→Oct 7, 2026 (actual)
Nov 9, 2026
Study completion
Dec 31, 2026→Oct 7, 2026 (actual)
Nov 9, 2026
Enrollment
8 (estimated)→10 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Completed
    Primary completion Sep 30, 2026→Oct 7, 2026 (now actual)
    Study completion Dec 31, 2026→Oct 7, 2026 (now actual)
    Enrollment 8 (estimated)→10 (actual)
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05464459
Lead sponsor
Wrightington, Wigan and Leigh NHS Foundation Trust
Collaborators
Edge Hill University
Responsible party
Sponsor
First posted
Jul 19, 2022
Start date
Oct 17, 2022
Primary completion
Oct 7, 2026
Completion
Oct 7, 2026
Last update
Nov 9, 2026

Study contacts

Adam Watts
principal investigator · Wrightington, Wigan & Leigh Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion